Merck Says Investigational Skin Therapy Shows Potential
Key takeaways
- Merck’s Phase 2b tulisokibart trial for hidradenitis suppurativa hit its primary endpoint, but the market reacted mildly negatively.
- High‑dose HiSCR50 72% (vs 35% placebo)
- Medium‑dose HiSCR50 64% (vs 35% placebo)
- Low‑dose HiSCR50 52% (vs 35% placebo)
What happened
Merck & Co Inc. (MRK) announced that its investigational monoclonal antibody tulisokibart met the primary endpoint in a Phase 2b trial for hidradenitis suppurativa, with 72% of high‑dose patients and 64% of medium‑dose patients achieving a 50% clinical response (HiSCR50) at week 16, compared to 35% in the placebo group.
Why it matters
The positive results suggest tulisokibart could become a new treatment option for a chronic skin disease that currently has limited therapies, potentially expanding Merck’s dermatology pipeline and adding a new revenue stream.
Short-term and longer-term
Short-term. Short‑term traders should note the modest share decline and the fact that the trial data, while positive, is still early Phase 2b.
Longer-term. Longer‑term investors may view this as a promising addition to Merck’s dermatology portfolio, potentially diversifying revenue beyond its traditional pharmaceuticals.